Roivant (ROIV) Halts CLE Program After IMVT-1402 Misses Primary Endpoint

Roivant said Immunovant’s IMVT-1402 proof-of-concept study in cutaneous lupus erythematosus did not meet the Week 12 primary endpoint, and development in CLE will stop. Other autoimmune indications for IMVT-1402 remain in development.Material DetailsContext by AI AnalystThis is an early-to-mid stag…